HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Medullary thyroid cancer: therapeutic targets and molecular markers.

AbstractPURPOSE OF REVIEW:
The present review will provide an update of important studies in medullary thyroid cancer (MTC) with an emphasis on targeted preclinical and translational research studies published over the past 2 years.
RECENT FINDINGS:
Recent advances in the biology of MTC, particularly in RET proto-oncogene signaling, are now being translated into promising new therapies and biomarkers. Multifunction tyrosine kinase inhibitors that target RET, plus vascular endothelial growth factor receptors and additional kinases, are now being evaluated in Phase II clinical trials in MTC. Important unanswered questions include the optimal means for selecting high-risk patients, appropriate biomarkers for monitoring kinase inhibitor trials, and trial endpoints. Similar to ABL, epidermal growth factor receptors and other kinases, individual mutant RET forms have differential sensitivity to different inhibitors. In addition to RET, an old marker, calcitonin, has assumed increasing importance, but may not adequately reflect changes in tumor burden in RET inhibitor trials. A number of new therapeutic strategies are being developed that could be appropriate for the approximately 50% of patients who lack RET mutations in their tumors.
SUMMARY:
Progress is being made toward effective targeted MTC therapy. Patients with advanced, progressive MTC should be considered for enrollment in clinical trials.
AuthorsDouglas W Ball
JournalCurrent opinion in oncology (Curr Opin Oncol) Vol. 19 Issue 1 Pg. 18-23 (Jan 2007) ISSN: 1040-8746 [Print] United States
PMID17133107 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
Chemical References
  • Antineoplastic Agents
  • Biomarkers, Tumor
Topics
  • Antineoplastic Agents (therapeutic use)
  • Biomarkers, Tumor (metabolism)
  • Carcinoma, Medullary (metabolism, pathology, therapy)
  • Humans
  • Thyroid Neoplasms (metabolism, pathology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: